Press Releases

Press Releases

Date Title
May 14, 2018
UNITY Biotechnology, Inc. Appoints Camille Landis as Senior Vice President of Corporate Development

SAN FRANCISCO , May 14, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Camille Landis as senior vice president of corporate development.

May 7, 2018
UNITY Biotechnology, Inc. Announces Closing of Initial Public Offering

BRISBANE, Calif. , May 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the closing of the Company’s initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, which does not include the exercise by the

May 2, 2018
UNITY Biotechnology, Inc. Announces Pricing of Initial Public Offering of Common Stock
BRISBANE, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.
March 27, 2018
UNITY Biotechnology, Inc. Appoints Pharmaceutical Industry Executive Paul L. Berns to Board of Directors
SAN FRANCISCO, March 27, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Paul L. Berns to its board of directors. Mr.
March 19, 2018
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing Proceeds to Support Advancement of Pipeline into Clinical Studies
SAN FRANCISCO, March 19, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the closing of a $55 million Series C financing.
February 7, 2018
UNITY Biotechnology Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors
SAN FRANCISCO, Feb. 7, 2018 /PRNewswire/ -- UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the appointment of David L. Lacey, M.D., to its board of directors. Dr.